CXCL12-3′ A polymorphism and lung cancer metastases protection: New perspectives in immunotherapy?

Cancer Immunology, Immunotherapy

Volumn 55, Issue 6, 2006, Pages 639-643

  Coelho, Ana ^a   Calçada, Carmen ^a   Catarino, Raquel ^a   Pinto, Daniela ^a   Fonseca, Graça ^a   Medeiros, Rui ^a  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

STROMAL CELL DERIVED FACTOR 1; ALPHA CHEMOKINE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CONTROLLED STUDY; DNA DETERMINATION; DNA EXTRACTION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; GENETICS; LUNG TUMOR; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; CHEMOKINES, CXC; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 33644591597     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0062-1     Document Type: Article

References (26)

1. Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4:540-550
2. Benovic JL, Marchese A (2004) A new key in breast cancer metastases. Cancer Cell 6:429-430
3. Epstein RJ (2004) The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer 4:1-9
4. Hart I, Fidler I (1980) Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 40:2281-2287
5. Hoffman PC, Mauer AM, Vokes EE (2000) Lung cancer. Lancet 355:479-485
6. Homey B, Muller A, Zlotnik A (2002) Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2:175-184
7. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
8. Kristiansen B, Knudsen TB, Ohlendorff S, Eugen-Olsen J (2001) A new multiplex PCR strategy for the simultaneous determination of four genetic polymorphisms affecting HIV-1 disease progression. J Immunol Methods 252:147-151
9. Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L, Allendorf DJ, Zhang J, Ratajczak J, Ratajczak MZ (2004) CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 35:233-245
10. Liotta LA (2001) An attractive force in metastasis. Nature 410:24-25
11. Miller S, Dykes D, Polesky H (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215
12. Minna JD, Roth JA, Gazdar AF (2002) Focus on lung cancer. Cancer Cell 1:49-52
13. Mochizuki H, Matsubara A, Teishima J, Mutaguchi K, Yasumoto H, Dahiya R, Usui T, Kamiya K (2004) Interaction of ligand-receptor system between stromal-cell derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis. Biochem Biophys Res Commun 320:656-663
14. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegul E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56
15. Murakami T, Cardones AR, Hwang ST (2004) Chemokine receptors and melanoma metastasis. J Dermatol Sci 36:71-78
16. Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2:533-543
17. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM (2003) The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 167:1676-1686
18. Proudfoot AEI (2002) Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2:106-115
19. Rosell R, Felip E, Garcia-Campelo R, Balaña C (2004) The biology of non-small-cell lung cancer: identifying new targets for rational therapy. Lung Cancer 46:135-148
20. Samara G, Lawrence D, Chiarelli CJ, Valentino MD, Lyubsky S, Zucker S, Vaday GG (2004) CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma. Cancer Lett 214:231-241
21. Schrader A, Lechner O, Templin M, Dittmar K, Machtens S, Mengel M, Probst-Kepper M, Franzke A, Wollensak T, Gatzlaff P, Atzpodien J, Buer J, Lauber J (2002) CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer 86:1250-1256
22. Soriano Á, Martínez C, García F, Plana M, Palou E, Lejeune M, Aróstegui JI, Lazzari ED, Rodriguez C, Barrasa A, Lorenzo JI, Alcamí J, Romero Jd, Miró JM, Gatell JM, Gallart T (2002) Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3′A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression. J Infect Dis 186:922-931
23. Strieter RM, belperio JA, Burdick MD, Sharma S, Dubinett SM, Keane MP (2004) CXC chemokines angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann NY Acad Sci 1028:1-10
24. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, Dean M, Honjo T, Tashiro K, Yabe D, Buchbinder S, Vittinghoff E, Goedert JJ, O'Brien TR, Jacobson LP, Detels R, Donfield S, Willoughby A, Gomperts E, Vlahov D, Phair J, O'Brien SJ (1998) Genetic restriction of AIDS pathogenesis by an SDF-I Chemokine Gene Variant. Sci 279:389-393
25. Zafiropoulos A, Crikas N, Passam AM, spandidos DA (2004) Significant involvement of CCR2-64I and CXCL12-3″A in the development of sporadic breast cancer. J Med Genet 41:e59
26. Zlotnik A (2004) Chemokines in neoplastic progression. Semin Cancer Biol 14:181-185